Catabasis Pharmaceuticals Inc (CATB) Rating Lowered to Hold at Zacks Investment Research
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
A number of other brokerages have also issued reports on CATB. Wedbush reaffirmed an “ourperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target (down from $14.00) on shares of Catabasis Pharmaceuticals in a research note on Tuesday, March 21st. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $9.00 price target (down from $11.00) on shares of Catabasis Pharmaceuticals in a research note on Monday. Citigroup Inc lowered Catabasis Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 1st. Finally, Cowen and Company lowered Catabasis Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $4.00 price target for the company. in a research note on Wednesday, February 1st. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.30.
Catabasis Pharmaceuticals (NASDAQ:CATB) traded up 0.75% during mid-day trading on Friday, reaching $1.35. The company’s stock had a trading volume of 227,561 shares. The firm’s market capitalization is $25.51 million. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $7.89. The firm’s 50 day moving average price is $1.43 and its 200 day moving average price is $2.54.
Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, March 16th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. On average, analysts anticipate that Catabasis Pharmaceuticals will post ($1.55) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Catabasis Pharmaceuticals Inc (CATB) Rating Lowered to Hold at Zacks Investment Research” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/05/19/catabasis-pharmaceuticals-inc-catb-rating-lowered-to-hold-at-zacks-investment-research.html.
Large investors have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC bought a new stake in Catabasis Pharmaceuticals during the third quarter valued at $138,000. Renaissance Technologies LLC bought a new stake in Catabasis Pharmaceuticals during the first quarter valued at $106,000. Oppenheimer & Co. Inc. bought a new stake in Catabasis Pharmaceuticals during the first quarter valued at $144,000. Federated Investors Inc. PA raised its stake in Catabasis Pharmaceuticals by 45.1% in the fourth quarter. Federated Investors Inc. PA now owns 160,000 shares of the biotechnology company’s stock valued at $578,000 after buying an additional 49,750 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its stake in Catabasis Pharmaceuticals by 13.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 223,885 shares of the biotechnology company’s stock valued at $808,000 after buying an additional 26,685 shares in the last quarter. 61.43% of the stock is owned by institutional investors and hedge funds.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.